All In Biotech

Drug Trial Radar · NCT04081103

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled Study to Assess the Efficacy and Safety of Nexagon® (NEXAGON) in Subjects With Corneal Persistent Epithelial Defects

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

35

Actual

Start

Jun 30, 2020

Primary completion

Feb 7, 2022

Study completion Feb 7, 2022

Sponsor

Lead sponsor
Glaukos CorporationIndustry
Sponsor type
Industry
Collaborators
Amber Ophthalmics, Inc.
First posted
Sep 9, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care for at least 14 days. It will assess the efficacy and safety of Nexagon® (lufepirsen) plus standard of care versus NEXAGON-vehicle (placebo) plus standard of care. The recovery of the corneal epithelium will be the primary outcome measure, defined as a cornea that re-epithelializes by Day 28 of treatment and remains re-epithelialized for at least a further 28 days.

Conditions

  • Corneal Persistent Epithelial Defect

Interventions

  • Nexagon® (lufepirsen) High Dose ConcentrationDrug

    Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.

  • Nexagon® (lufepirsen) Low Dose ConcentrationDrug

    Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.

  • VehicleDrug

    Vehicle is administered topically in the affected eye three (3) times over 28 days.

  • Open-label Nexagon® (lufepirsen)Drug

    Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Proportion of Subjects Achieving Corneal Epithelial Recovery, as Assessed by Slit Lamp Examination.Time frame: Up to 56 days.
  2. Incidence of Treatment Emergent Adverse Events as Assessed by CTCAE v 5.0Time frame: Up to 30 days after last application of intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jules Stein Eye Institute

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.